glp 1 for nash GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD) | Current Hepatology Reports Possible hepatoprotective effects of GLP-1
Description
Hypothalamic inflammation in obesity and metabolic disease
GLP-1 therapies have demonstrated substantial weight-reduction benefits, with studies showing an average weight loss of 4.6 kg, a BMI reduction of 2.1 kg/m, and a decrease in waist circumference of 4.6 cm compared to placebo
Research suggests that adequate protein intake, regular resistance training, and proper nutrition can help preserve muscle during weight loss
[66] showed that GLP-1 receptor expression levels were significantly inversely associated with the Gleason score of human prostate cancer tissues
